Denali Therapeutics Inc (DNLI) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

DNLI ranks #2145 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DNLI is a disclosed holding of Baillie Gifford (Baillie Gifford & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 0.3% of that fund's own 13F portfolio.

DNLI is a top-conviction position for Crestline Management, L.P. — at 91.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DNLI belongs to T. Rowe Price Investment Management, Inc., but the position matters far more to Crestline Management, L.P., who has 91.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

T. Rowe Price has added to its DNLI position for two straight quarters, increasing it by $296.4M to reach $416.1M today.

Masters Capital Management LLC has trimmed its DNLI position for two straight quarters, cutting it by $11.4M while still holding $5.1M.

DNLI is down 1.8% today, but institutions show net buying of $465.4M this quarter — a divergence between today's price move and the underlying institutional flow.

DNLI reported a net loss of $511.5M over the trailing twelve months.

• Not yet profitable — net loss of $511.5M over the trailing twelve months
• Net income declined year over year, from -$479.0M to -$511.5M
• Operating cash flow was negative, using $412.6M in cash
• Current ratio of 9.16x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.13x equity — within a conventional range